Kalowski Lee sold $11K of QTTB

Kalowski Lee (CFO and President) sold 1,301 shares of Q32 Bio Inc. (QTTB) at $8.32 on 2026-10-06.

Original reporting
SEC EDGAR · Kalowski Lee
Published Oct 14, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QTTB
Bearish
high confidence
Mentioned
$QTTB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QTTBBearishLow
01

Why it matters

The CFO's modest sale is unlikely to move the stock significantly but adds to the flow of insider activity data.

02

Market read

A routine insider sale with limited market impact; primarily of interest to investors tracking insider activity.

03

What to watch

No pre‑arranged 10b5‑1 plan and the CFO retains a large stake, suggesting confidence in the company's prospects.

Relevance 3/10Novelty 3/10Timing: after-hours filing today

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$QTTBBearishHigh confidence
Context

CFO Kalowski Lee sold 1,301 shares for $10,824, reducing his stake in Q32 Bio.

Expected impact

likely modest pressure as the market prices in the insider sale

Evidence & confidence

The sale is small relative to holdings (1,301 of 137,170) and typical for insiders; impact is limited but could prompt short‑term downside bias.

Market effects

None

None

None

Counterpoint

The sale may be routine and not indicative of any fundamental weakness; investors could view it as a neutral event.

Key entities

  • Kalowski Lee

    CFO and President of Q32 Bio Inc.

  • Q32 Bio Inc.

    Biotech firm listed on Nasdaq under ticker QTTB.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QTTBMedAI 8/10

Q32 Bio Reports Q3 Results; Advances Bempikibart Toward Phase 3 In Alopecia Areata

Q32 Bio (QTTB) reported Q3 2026 results, with R&D expenses rising to $5.1M and net loss increasing to $8.9M. The company presented Phase 2a trial data for bempikibart, showing a 35.3% mean reduction in SALT scores for alopecia areata patients. Q32 Bio plans to initiate a Phase 3 trial in early 2027 and has $289.6M in cash reserves. The stock is currently trading at $8.81, up 0.57%.

$QTTBLow

Q32 Bio 3Q 2026: Net loss $8.9M, EPS $(0.26) — 10-Q Summary

Q32 Bio reported a Q3 2026 net loss of $8.9M, up 20.7% YoY, with EPS loss narrowing to $0.26. The company's bempikibart study showed improved SALT scores and no serious adverse events. Q32 plans regulatory discussions in Q4 2026 and aims to advance bempikibart in early 2027. Akebia will develop ADX-097 after the asset sale.

$QTTBMedAI 8/10

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio reported Q3 2026 results, highlighting positive SIGNAL-AA clinical trial data for bempikibart, a treatment for alopecia areata. The company presented 36-week results and 16-week off-drug findings at EADV Congress, showing durable responses. Q32 Bio plans to initiate a registration-directed program in 1H 2027 and has $289.6M in cash. The company also strengthened its leadership team and expects Phase 3 topline results from the planned program.